RXDX News and Press, Prometheus Biosciences Inc.

2023-05-31 08:54:58 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a globally synchronized world, there are big opportunities across sectors. This has intensified competition as companies look to grab a share of the pie. It eventually boils down to the su...

2023-05-30 22:04:25 ET Summary Merck has agreed to acquire clinical-stage biotech company Prometheus Biosciences for $200 per share in cash, with the deal expected to close late in Q2 or early in Q3. The acquisition will advance Merck's presence in immunology, focusing on late-sta...

2023-05-30 15:02:46 ET Summary Iveric bio, Inc., focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc. Iveric bio, Inc. stock trades at a discount of over 5% for an acquisition that is targeted to close in the third calendar q...

NEW YORK, NY / ACCESSWIRE / May 25, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Prometheus Biosciences, Inc. (NASDAQ:RXDX...

2023-05-23 08:55:42 ET Prometheus Biosciences ( NASDAQ: RXDX ) rose 2.8% in premarket trading after the HSR waiting period for the company's planned $11 billion sale to Merck ( NYSE: MRK ) expired. The HSR waiting period expired on Monday, according to a proxy fi...

2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...

2023-05-09 18:02:39 ET Prometheus Biosciences press release ( NASDAQ: RXDX ): Q1 GAAP EPS of -$0.86 beats by $0.06 . Revenue of $1.11M (-71.7% Y/Y) beats by $0.65M . For further details see: Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenu...

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated disease...

2023-05-04 16:20:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2023, Baron Health Care Fund declined 3.69%, compared w...

2023-05-01 13:29:00 ET Abbvie ( ABBV ) and Bristol-Myers Squibb ( BMY ) competed to takeover Prometheus Biosciences ( NASDAQ: RXDX ), before Merck ( NYSE: MRK ) won in its pursuit of the biotech company. The interest from other unidentified suitors for Prometheus...